MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
Soleno Therapeutics Operating Income 2011-2026 | SLNO
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Soleno Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -188 M | -41.4 M | -24.4 M | -31.5 M | -36.3 M | -23.5 M | -14.3 M | -12.2 M | -8.32 M | -12.2 M | -5.16 M | -847 K | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -847 K | -188 M | -33.1 M |
Quarterly Operating Income Soleno Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 22.1 M | -6.52 M | -45.7 M | - | -80.2 M | -24.9 M | -23.5 M | - | -10.4 M | -8.62 M | -8.47 M | - | -6.24 M | -6.78 M | -5.77 M | - | -8.29 M | -11.1 M | -9.16 M | - | -7.86 M | -11.2 M | -9.28 M | - | -6.13 M | -5.62 M | -4.98 M | - | -3.88 M | -3.41 M | -3.48 M | - | -2.63 M | -2.97 M | -1.37 M | - | -1.97 M | -2.3 M | -4.26 M | - | -3.18 M | -3.04 M | -2.43 M | - | -1.32 M | -1.31 M | -684 K | - | -993 K | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 22.1 M | -80.2 M | -8.59 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Brainsway Ltd.
BWAY
|
-5 M | $ 19.14 | 0.63 % | $ 99.4 M |  Israel |
 |
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M |  USA |
 |
Burning Rock Biotech Limited
BNR
|
-797 M | $ 19.97 | -4.84 % | $ 215 M |  China |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
BioNano Genomics
BNGO
|
-104 M | $ 1.59 | 3.59 % | $ 2.02 M | USA |
 |
Co-Diagnostics
CODX
|
-42.7 M | $ 5.64 | 11.51 % | $ 166 M | USA |
 |
Castle Biosciences
CSTL
|
8.67 M | $ 38.43 | -1.21 % | $ 1.07 B | USA |
 |
Danaher Corporation
DHR
|
4.86 B | $ 230.25 | 0.53 % | $ 168 B | USA |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
DarioHealth Corp.
DRIO
|
-56.2 M | $ 10.5 | -7.73 % | $ 298 M | Israel |
 |
DexCom
DXCM
|
598 M | $ 66.65 | 0.42 % | $ 25.7 B | USA |
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M | China |
 |
Exact Sciences Corporation
EXAS
|
-876 M | $ 101.69 | 0.13 % | $ 18.8 B | USA |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
Fulgent Genetics
FLGT
|
-73.9 M | $ 25.65 | -2.37 % | $ 776 M | USA |
 |
CareDx, Inc
CDNA
|
-203 M | $ 19.11 | 1.43 % | $ 1.03 B | USA |
 |
Celcuity
CELC
|
-113 M | $ 100.55 | 0.81 % | $ 3.97 B | USA |
 |
Anixa Biosciences
ANIX
|
-13.8 M | $ 3.14 | 0.64 % | $ 100 K | USA |
 |
Guardant Health
GH
|
-444 M | $ 101.73 | -0.4 % | $ 12.5 B | USA |
 |
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Aspira Women's Health
AWH
|
-32.8 M | - | -6.19 % | $ 10.5 M | USA |
 |
IQVIA Holdings
IQV
|
2.2 B | $ 225.49 | 0.08 % | $ 40.9 B | USA |
 |
Illumina
ILMN
|
-833 M | $ 134.02 | 2.18 % | $ 21.3 B | USA |
 |
Charles River Laboratories International
CRL
|
227 M | $ 201.62 | 1.09 % | $ 10.4 B | USA |
 |
OPKO Health
OPK
|
-152 M | $ 1.3 | 2.78 % | $ 902 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.35 B | $ 173.33 | -0.05 % | $ 19.2 B | USA |
|
Biodesix
BDSX
|
-34.5 M | $ 6.37 | -6.32 % | $ 826 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
553 M | $ 27.15 | 0.22 % | $ 20 B |  Niderland |
 |
Laboratory Corporation of America Holdings
LH
|
1.09 B | $ 251.35 | 0.14 % | $ 21.1 B | USA |
 |
Motus GI Holdings
MOTS
|
-11.9 M | - | -34.28 % | $ 263 K | Israel |
 |
ICON Public Limited Company
ICLR
|
1.1 B | $ 187.85 | 3.09 % | $ 15.5 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
1.13 B | $ 671.36 | -0.76 % | $ 55.4 B | USA |
 |
Lantheus Holdings
LNTH
|
457 M | $ 67.25 | 1.05 % | $ 4.65 B | USA |
 |
Agilent Technologies
A
|
1.35 B | $ 137.32 | 0.87 % | $ 41.7 B | USA |
 |
Organovo Holdings
ONVO
|
-12.6 M | - | -2.3 % | $ 19.4 M | USA |
 |
Personalis
PSNL
|
-68.3 M | $ 7.85 | -1.44 % | $ 465 M | USA |
 |
Biomerica
BMRA
|
-5.14 M | $ 2.51 | -0.39 % | $ 5.77 M | USA |
 |
Bioventus
BVS
|
-81.7 M | $ 7.23 | -2.82 % | $ 453 M | USA |
 |
Myriad Genetics
MYGN
|
-124 M | $ 6.18 | 0.41 % | $ 560 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-25.9 M | - | - | $ 9.42 M | Israel |